Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2018, Vol. 23 ›› Issue (6): 667-671.doi: 10.12092/j.issn.1009-2501.2018.06.011

Previous Articles     Next Articles

Study of the primary target and mutation position in nemonoxacin-resistant mutants of Staphlococcus aureus

LI Zhaoxia1, WANG Rui2,LI Aimin3,LIU Youning3   

  1. 1 Deparment of Oncology,PLA Rocket Force General Hospital,2 Laboratory of Clinical Pharmacology,3 Department of Pneumology,PLA General Hospital,Beijing 100088,China
  • Received:2018-01-04 Revised:2018-03-21 Online:2018-06-26 Published:2018-06-19

Abstract:

AIM: To determine the primary target of nemonoxacin and mutation position in S. aureus by genomic characterization of first and second step mutants. METHODS: Quinolone resistance-determining region(QRDR)mutations of gyrA, gyrB, and grlA of resistant mutants were identified by PCR amplification and gene sequencing. RESULTS: All the 4 first step mutants selected using nemonoxacin contained changes at codon 86, 439, and 440, but did not lead to amino acid substitution. For second-step mutants selected from first-step resistance strains, a novel second gyrA mutation (Ser-84→Leu) mutations was found. No mutations were found in grlA region of QRDR. CONCLUSION: DNA gyrase is the primary target of nemonoxacin in S. aureus. Mutation at position 84 may be the most important factor to influence the sensitivity of S. aureus.

Key words: nemonoxacin, staphlococcus aureus, drug resistance, mutation position

CLC Number: